Medical Condition News

RSS

Specific brain changes suggest new therapeutic targets for Alzheimer's disease

New studies identify brain changes in people with Alzheimer's disease. The results give researchers a greater understanding of the disease and may help at-risk individuals by improving early detection. New animal research also shows a novel approach to Alzheimer's vaccine design that may avoid dangerous side effects. These new results were reported at Neuroscience 2010, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

17 Nov 2010

CDH Proton Center commences treatment with IBA's Proteus 235 proton delivery system

IBA (Ion Beam Applications S.A.) and ProCure Treatment Centers, Inc., (ProCure) announced today that the CDH Proton Center, A ProCure Center, located outside Chicago, recently delivered proton radiation treatment to its first patients using IBA's Proteus 235 proton delivery system. It took only 24 months to build the facility, install the equipment and treat the first patient, setting a new world record in bringing this important technology to patients who could benefit.

17 Nov 2010

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

PrecisionMed Inc. today announced at the Society for Neuroscience annual meeting in San Diego, enrollment of the first subject into the PrecisionMed Multiple Sclerosis (MS) Registry. The PrecisionMed MS Registry is a biological sample bank of DNA and serial RNA, CSF, serum and plasma associated with serial clinical testing utilizing PrecisionMed's clinical data procurement and storage capabilities.

17 Nov 2010

New OncoMap technique can detect point mutation in ovarian cancer

Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.

17 Nov 2010

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Alkermes, Inc. today announced the presentation of promising preclinical results for its proprietary opioid modulator, ALKS 33, showing the drug candidate's potential in multiple disease indications.

17 Nov 2010

Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer

Treatment of inoperable advanced liver cancer with the agent doxorubicin (routinely used to treat this condition) in addition to the agent sorafenib resulted in greater overall survival and progression-free survival, compared to patients who received treatment with doxorubicin alone, according to a study in the November 17 issue of JAMA.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Metallic particles in smoke from fireworks affect human health

The metallic particles in the smoke emitted by fireworks pose a health risk, particularly to people who suffer from asthma. This is the conclusion of a study led by researchers from the Institute of Environmental Assessment and Water Research (IDAEA-CSIC), published this week in the Journal of Hazardous Materials.

17 Nov 2010

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient/Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel)

17 Nov 2010

Study suggests cross-infection with P aeruginosa occurs between CF centers in the UK and Canada

A common transmissible strain of the bacteria Pseudomonas aeruginosa has been identified among cystic fibrosis (CF) patients in Canada, suggesting that cross-infection has occurred widely between CF centers in the United Kingdom and Canada, according to a study in the November 17 issue of JAMA. Infection with this strain among Canadian CF patients has been associated with an increased risk of death or lung transplantation.

17 Nov 2010

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.

17 Nov 2010

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Doctors across the United States are taking a wait-and-see approach while Congress decides whether or not to allow a scheduled 23% cut in Medicare reimbursement rates to take effect on Dec. 1.

17 Nov 2010

Researchers explore interplay between pain and anxiety

Disability from chronic pain in adolescents can be exacerbated by high levels of anxiety, according to research reported The Journal of Pain, the peer review publication of the American Pain Society.

17 Nov 2010

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Avedro's KXL System for corneal cross-linking granted European CE Mark

Avedro, Inc., sponsor of two completed US FDA multi-center clinical trials for corneal cross-linking, today announced that its KXL™ System for performing accelerated corneal cross-linking (KXL) has received the European Union's CE Mark. The CE Mark certifies that the KXL System has met the EU's health and safety standards and opens the door to immediate commercialization across the European Economic Community and in other countries recognizing the CE Mark.

17 Nov 2010

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.

17 Nov 2010

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics Pharmaceuticals, Inc. today announced the initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. The drug, designated ONO-3849 in Japan, is being evaluated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness such as cancer.

17 Nov 2010

Neurologic complications remain an important cause of morbidity and mortality after heart surgeries

Strokes, seizures and other neurological complications related to heart surgery account for "considerable morbidity and mortality," Loyola University Health System neurologists report in the November issue of the journal Hospital Practice.

16 Nov 2010

AEDs do not improve rate of survival for in-hospital cardiac arrests

While automated external defibrillators improve survival for out-of-hospital cardiac arrest, an analysis of data indicates their use for cardiac arrest in a hospital does not result in an improved rate of survival, according to a study in the November 17 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

16 Nov 2010

Medical Condition News

Specific brain changes suggest new therapeutic targets for Alzheimer's disease

CDH Proton Center commences treatment with IBA's Proteus 235 proton delivery system

PrecisionMed enrolls first subject in Multiple Sclerosis Registry

New OncoMap technique can detect point mutation in ovarian cancer

Alkermes's ALKS 33 drug candidate offers potential treatment for multiple disease indications

Combination doxorubicin-sorafenib treatment improves survival in patients with inoperable advanced liver cancer

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Metallic particles in smoke from fireworks affect human health

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

Study suggests cross-infection with P aeruginosa occurs between CF centers in the UK and Canada

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Researchers explore interplay between pain and anxiety

Study: EGFR inhibtion may help treat triple negative breast cancer

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Avedro's KXL System for corneal cross-linking granted European CE Mark

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Neurologic complications remain an important cause of morbidity and mortality after heart surgeries

AEDs do not improve rate of survival for in-hospital cardiac arrests

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Latest News